Pugliese Alberto
J Clin Invest. 2017 Aug 1;127(8):2881-2891. doi: 10.1172/JCI94549.
Type 1 diabetes (T1D) is a chronic autoimmune disease that causes severe loss of pancreatic β cells. Autoreactive T cells are key mediators of β cell destruction. Studies of organ donors with T1D that have examined T cells in pancreas, the diabetogenic insulitis lesion, and lymphoid tissues have revealed a broad repertoire of target antigens and T cell receptor (TCR) usage, with initial evidence of public TCR sequences that are shared by individuals with T1D. Neoepitopes derived from post-translational modifications of native antigens are emerging as novel targets that are more likely to evade self-tolerance. Further studies will determine whether T cell responses to neoepitopes are major disease drivers that could impact prediction, prevention, and therapy. This Review provides an overview of recent progress in our knowledge of autoreactive T cells that has emerged from experimental and clinical research as well as pathology investigations.
1型糖尿病(T1D)是一种慢性自身免疫性疾病,可导致胰腺β细胞严重受损。自身反应性T细胞是β细胞破坏的关键介质。对患有T1D的器官捐献者进行的研究,检测了胰腺、致糖尿病性胰岛炎病变和淋巴组织中的T细胞,结果显示了广泛的靶抗原和T细胞受体(TCR)使用情况,初步证据表明T1D患者存在共享的公共TCR序列。源自天然抗原翻译后修饰的新表位正在成为更有可能逃避自身耐受的新靶点。进一步的研究将确定T细胞对新表位的反应是否是影响预测、预防和治疗的主要疾病驱动因素。本综述概述了来自实验和临床研究以及病理学调查的关于自身反应性T细胞的最新知识进展。